Novavax is trading at $9.01, up +7.01%, with no clear company-specific announcement, filing, analyst action, or regulatory catalyst identified for August 21, 2026.
- Recent coverage focused on August 6 second-quarter results, when Novavax raised its 2026 revenue outlook to $235 million–$275 million.
- The August 19 vaccine-sector rally followed positive Moderna and Merck cancer-vaccine results, but that catalyst does not directly explain today’s gain.
- The move is therefore currently unexplained and may reflect short-term trading or positioning.